Search
Now showing items 1-5 of 5
-
Chloroquine : les preuves pré-cliniques sont suffisantes pour justifier la recherche clinique sur ses effets sur le COVID-19
(2020-04-08)Citation: Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care 2020 [Epub ahead of print]. De quoi s’agit-il ... -
Cerebrolysin for acute ischaemic stroke
(2020-07-14)Background: Cerebrolysin is a mixture of low‐molecular‐weight peptides and amino acids derived from porcine brain that has potential neuroprotective properties. It is widely used in the treatment of acute ischaemic stroke ... -
What are the risk factors and effectiveness of prophylaxis for venous thromboembolism in COVID-19 patients?
(2020-07-10)BACKGROUND: An emerging issue in the management of the novel COVID-19 coronavirus is morbidity and mortality associated with venous thrombolytic events. Apart from respiratory failure, coagulopathy is a common abnormality ... -
Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives
(2020-06-30)A life-threatening respiratory illness (COVID-19) due to severe acute respiratory syndrome (SARS)-CoV-2 coronavirus was first described in December 2019 in Wuhan (China), rapidly evolving into a pandemic. In the first ... -
Azithromycine : les effets sur le traitement de COVID-19 sont incertains
(2020-07-16)Citation: Gbinigie K, Frie K. Should azithromycin be used to treat COVID-19? A rapid review. BJGP open. 2020 Jun 23;4(2):bjgpopen20X101094 Quel est le contenu ? Azithromycine a été suggéré comme traitement possible pour ...